Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Maan Jamal

Internal Medicine Warren, MI Medical Doctor

NPI 1326072471 CMS profile 1055663

27550 Hoover Rd, Warren, MI 48093

Open in the dashboard

General payments

$4,403

232 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maan Jamal of Warren, MI is reported in the CMS Open Payments database as having received $4,403 across 232 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,295 129
2024 General $800 40
2023 General $1,148 53
2022 General $160 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maan Jamal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Maan Jamal were reported at $2,295. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Maan Jamal Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $160 $141 $42–$496 $149
2023 $1,148 $149 $45–$519 $160
2024 $800 $154 $47–$537 $164
2025 $2,295 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $1,280 83 payments
  2. AstraZeneca Pharmaceuticals LP $610 21 payments
  3. Verona Pharma, Inc. $607 41 payments
  4. Regeneron Healthcare Solutions, Inc. $425 14 payments
  5. Amgen Inc. $286 10 payments
  6. Insmed, Inc. $195 16 payments
  7. Novo Nordisk Inc $159 8 payments
  8. Genzyme Corporation $136 3 payments
  9. Otsuka America Pharmaceutical, Inc. $114 5 payments
  10. AbbVie, Inc. $94 5 payments
  11. Other $497 26 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,403 232 payments
Products named General payments · program years 2022–2025
  1. TRELEGY ELLIPTA $683 54 payments
  2. Ohtuvayre $607 41 payments
  3. NUCALA $461 25 payments
  4. AIRSUPRA $378 14 payments
  5. DUPIXENT Inflammation And Immunology $303 9 payments
  6. Arikayce $195 16 payments
  7. BREZTRI $186 5 payments
  8. Repatha $181 5 payments
  9. AREXVY $136 4 payments
  10. DUPIXENT Immunology $136 3 payments
  11. Other $1,597 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

3,046

Median for Pulmonary Disease: 936

Drug cost

$617,618

Median for Pulmonary Disease: $487,987

Branded share of claims

33%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 118 $129,628
Trulicity Dulaglutide Brand 70 $94,111
Mounjaro Tirzepatide Brand 46 $57,538
Eliquis Apixaban Brand 51 $51,694
Breo Ellipta Fluticasone/Vilanterol Brand 64 $43,544
Spiriva Respimat Tiotropium Bromide Brand 44 $37,945
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 40 $36,193
Incruse Ellipta Umeclidinium Bromide Brand 54 $27,252
Linzess Linaclotide Brand 36 $27,009
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 31 $21,539

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$212,620

Of which drugs: $2,773

Medicare patients

362

Average age 77

Services billed

4,105

189 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 71%
Arthritis 62%
Ischemic heart disease 61%
Diabetes 60%
Heart failure 56%
Chronic kidney disease 47%
Atrial fibrillation 46%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 31 31 $2,455
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 29 116 $108
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 17 100 $9
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 Office 11 12 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $187
$187 118 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $119
$119 22 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $118
$118 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $80
  • GENZYME CORPORATION $35
$115 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $44
$44 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

232 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record